TABLE 4.

Univariate and multivariate survival analysis for validation sets.

	Validation set 1			Validation set 2
	HR	95% CI	p-value	HR	95% CI	p-value
Univariate analysis
Age (3–6 vs. 6–9 vs. 9–12 vs. 12–15 vs. 15–18 vs. 18+)	1	0.86–1.2	0.75	0.76	0.42–1.4	0.37
Gender (male vs. female)	1.4	0.7–3	0.33	0.78	0.23–2.6	0.69
Histology (classic vs. Des vs. LCA vs. MBEN)	1.7	1–2.7	0.044*	1.4	0.81–2.5	0.23
Risk Group (low vs. high)	0.31	0.17–0.58	0.00022*	0.14	0.037–0.51	0.003*
Subgroup (SHH vs. WNT vs. Group 3 vs. Group 4)	1	0.8–1.4	0.73	0.8	0.5–1.3	0.35
Multivariate analysis
Age (3–6 vs. 6–9 vs. 9–12 vs. 12–15 vs. 15–18 vs. 18+)	1.17	0.95–1.47	0.14	0.77	0.41–1.44	0.41
Gender (male vs. female)	1.08	0.51–2.30	0.84	0.86	0.20–3.64	0.84
Histology (classic vs. Des vs. LCA vs. MBEN)	1.51	0.89–2.52	0.12	1.48	0.78–2.78	0.23
Risk Group (low vs. high)	0.3	0.14–0.61	0.00107*	0.14	0.04–0.54	0.00407*
Subgroup (SHH vs. WNT vs. Group 3 vs. Group 4)	1.23	0.89–1.68	0.21	0.83	0.47–1.45	0.51

HR, hazard ratio; CI, confidence interval; Des, desmoplastic/nodular; LCA, large-cell anaplastic; MBEN, medulloblastoma with extensive nodularity; SHH, sonic hedgehog; WNT, Wingless.